Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Biovitrum AB
Femme et Homme Max 99 ans
Swedish Orphan Biovitrum AB
MAJ Il y a 4 ans
Taste and palatability of Orfadin suspension
To determine the acceptability of the suspension in the pediatric population.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Biovitrum AB
MAJ Il y a 4 ans
A double-blind, placebo-controlled, randomized, parallel-group study evaluating the efficacy and tolerability of oral BVT.115959, a novel A2A agonist, versus placebo in the treatment of diabetic neuropathic pain
To compare the analgesic properties of BVT.115959 in subjects with diabetic neuropathic pain against placebo following 4 weeks’ treatment.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Biovitrum AB
MAJ Il y a 4 ans
An open label, exploratory study on the effect of rhBSSL on the fat absorption in patients with cystic fibrosis and pancreatic insufficiency
To assess the effect of rhBSSL on the coefficient of fat absorption in patients with cystic fibrosis and pancreatic insufficiency, following administration of a fixed daily dose of rhBSSL.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Swedish Orphan Biovitrum AB (Publ)
MAJ Il y a 4 ans
An open-label, non-randomized, sequential, multicenter study to evaluate the pharmacokinetics, efficacy and safety of once daily dosing compared to twice daily dosing of Orfadin in patients diagnosed with hereditary tyrosinemia type 1
To evaluate the steady-state exposure to nitisinone during once and twice daily dosing of Orfadin
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Biovitrum AB
MAJ Il y a 4 ans
A prospective, randomised, double-blind crossover study comparing 0.15 g/L rhBSSL added to infant formula versus placebo during one week of treatment in preterm infants born before week 32 of gestational age
The primary objective of this study is to compare the fat absorption (coefficient of fat absorption) in preterm infants following treatment with rhBSSL to that with placebo when administered in infant...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Swedish Orphan Biovitrum AB (Publ)
MAJ Il y a 4 ans
A phase 3 clinical study investigating the effects of rhBSSL (an enzyme to help digestion of fat) added to pasteurized breast milk or formula in babies born prematurely
The primary objective of this study is to demonstrate that rhBSSL improves growth in preterm infants as compared with placebo when administered in infant formula or PBM.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Swedish Orphan Biovitrum AB (Publ)
MAJ Il y a 4 ans
To determine a safe and tolerable dose of palifermin in pediatric subjects of different age groups when administered once daily for 3 consecutive days before and 3 consecutive days after a myeloablative chemo-radiotherapy conditioning regimen with allogeneic hematopoietic stem cell transplant (HSCT)
To determine a safe and tolerable dose of palifermin in pediatric subjects of different age groups when administered once daily for 3 consecutive days before and 3 consecutive days after a myeloablati...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme et Homme Max 99 ans
Biovitrum AB
MAJ Il y a 4 ans
A prospective, randomised, double-blind crossover study comparing 0.15 g/L rhBSSL added to pasteurized breast milk versus placebo during one week of treatment in preterm infants born before week 32 of gestational age
The primary objective of this study is to compare the fat absorption (coefficient of fat absorption) in preterm infants following treatment with rhBSSL to that with placebo when administered in pasteu...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Biovitrum AB
MAJ Il y a 4 ans
A 4-week, double-masked, parallel-group, randomized , multicenter, proof of concept study comparing the efficacy and safety of two dose levels of BVT.28949 with placebo in patients with ocular hypertension or open angle glaucoma
The primary objective is to compare mean reduction in diurnal IOP between each of the two groups receiving BVT.28949 (2 mg/mL, 7 mg/mL) and the placebo group after 4 weeks of treatment.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Swedish Orphan Biovitrum AB (Publ)
MAJ Il y a 4 ans
A study to evaluate the effects of palifermin in reducing mouth ulceration in subjects with locally advanced head and neck cancer
To evaluate the pharmacokinetic profile and biological activity on buccal mucosae of palifermin administered at the dose of 120 μg/kg IV in a cohort of at least 16 (3 palifermin : 1 placebo) locally a...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations